Xenetic Biosciences Inc (NASDAQ:XBIO), which happens to be one of the top and trusted clinical-stage biopharmaceutical companies globally focusing on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, has today broken its silence on the most awaited news.
It has made it pretty clear for all the concerned parties that indeed it has received the expected update in line with the Phase 1/2 clinical study which was reportedly conducted by its partner Shire, evaluating SHP656 (“PSA-recombinant Factor VIII”, “PSA-rFVIII”), and sources indicate that it is being manufactured as a long-acting therapeutic that will significantly aid in the treatment of hemophilia A.
As a matter of fact, it is expected to utilize Xenetic’s PolyXen™ platform technology that will facilitate the conjugation of polysialic acid to therapeutic blood-clotting factors.
Some of the close sources indicate that the Phase 1/2 study elaborately demonstrated SHP656’s efficacy and this was termed a great sign by some top experts.
Xenetic’s Chief Executive Officer, M. Scott Maguire in a press briefing said, “Despite not achieving the principal objective of once-weekly dosing in this Phase 1/2 study, our PolyXen technology clearly works as a platform to successfully extend the circulating half-life of rFVIII with no drug-related serious adverse events.
He proceeded, “Including our own studies with a polysialylated erythropoietin (“PSA-EPO”, “ErepoXen®”) candidate, this is the second instance in which PolyXen has been demonstrated, in a human clinical trial setting, to confer extended half-life to a biotherapeutic, while maintaining pharmacological activity and a favorable safety and tolerability profile.”
Xenetic Biosciences Inc, just like the rest of the top companies has had its affair share of challenges in business, but one thing that is for sure is that it has remained vigilant in its business undertakings.
Having tried out various strategies, some of which ended up in futility, most of its top officials firmly believe that the company is headed to the right direction and that it will see to it that patients across the globe access top notch solutions. A lot of resources are being directed into research, but they hope it pays off in the long run.